Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cystagon plus standard therapy for pulmonary tuberculosis
2024-516088-10-00Phase 2Authorised
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cysteamine in pulmonary tuberculosis (TB), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoints: Acceptability of treatment, Adherence to cysteamine and 4 more. Planned start Oct 2024; status: authorised.
02
Drugs
cysteamine
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2024-516088-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516088-10-00.